ProCE Banner Activity

CE

Management of Eosinophilic Esophagitis: Opportunities for Pharmacists to Increase Awareness and Optimize Care

Video

Tune in for the latest updates on eosinophilic esophagitis and the pharmacist’s role in collaborative care to optimize overall management, patient and disease outcomes, and transitions of care with this on-demand webcast, downloadable slides, and a ClinicalThought commentary on the most compelling questions asked at the live symposium.

Pharmacists: 1.50 contact hours (0.15 CEUs)

Released: April 25, 2023

Expiration: April 24, 2024

No longer available for credit.

Share

Faculty

Brian A. Hemstreet

Brian A. Hemstreet, PharmD, FCCP, BCPS

Associate Dean and Professor
Department of Clinical Pharmacy
University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences
Aurora, Colorado

Erin Hamai Tom

Erin Hamai Tom, PharmD, APh, MBA, BCACP, CSP

Clinical Manager
Specialty Pharmacy
UC Davis Health
Sacramento, California

Provided by

This activity is provided by ProCE, LLC

ProCE Banner

Supporters

This activity is supported by an educational grant from Regeneron Pharmaceuticals, Inc., and Sanofi.

Regeneron Pharmaceuticals, Inc.

Sanofi

Target Audience

The target audience for this activity is pharmacists, including managed care, specialty, and clinical pharmacists, who care for patients with EoE, as well as pharmacy directors, chief pharmacy officers, and other stakeholders in pharmacy practice.

Program Learning Goal

The goal of this activity is to improve the knowledge and competence of learners about EoE, treatment options, and the role of the pharmacist in EoE management to improve patient outcomes.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Describe the pathophysiology and burden of disease in EoE

  • Evaluate current and emerging therapies based on their impact on disease outcomes in patients with EoE

  • Identify strategies for coordinating with the multidisciplinary team to improve health-related quality of life and outcomes for patients with EoE

  • Discuss the role of the pharmacist in EoE disease management, including in transitions of care

Disclosure

ProCE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to ProCE policy. ProCE is committed to providing its learning with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of ineligible company.

The faculty reported the following relevant financial relationships to products or devices they have with ineligible companies related to the content of this educational activity.

Primary Author

Brian A. Hemstreet, PharmD, FCCP, BCPS

Associate Dean and Professor
Department of Clinical Pharmacy
University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences
Aurora, Colorado

Brian Hemstreet, PharmD, FCCP, BCPS, has no relevant financial relationships to disclose.

Erin Hamai Tom, PharmD, APh, MBA, BCACP, CSP

Clinical Manager
Specialty Pharmacy
UC Davis Health
Sacramento, California

Erin Hamai Tom, PharmD, APh, MBA, BCACP, CSP: consultant/advisor/speaker: Janssen.

The planners and content peer reviewers from ProCE, LLC do not have any relevant financial relationships to disclose.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Learners have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by healthcare professionals without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities

Accreditation

Pharmacists

ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-0000-23-004-H01-P has been assigned to this home study application-based activity. This activity is approved for 1.5 contact hours (0.15 CEU) in states that recognize ACPE providers. The activity is provided at no cost to participants. Completion of the evaluation and the post-test with a score of 65% or higher are required to receive CE credit. No partial credit will be given. Statements of completion will be issued online at www.ProCE.com, and proof of completion will be posted in NABP CPE Monitor profiles.